Publication: Asthma – Inhaled Corticosteroids (ICS): different molecules - different devices – different treatment concepts: what really makes a difference?
Files
Date
2024
Journal Title
Journal ISSN
Volume Title
Publisher
Nepalese Respiratory Society
Abstract
Abstract
Bronchial asthma is a chronic, heterogeneous disease with different clinical phenotypes and inflammatory endotypes. Anti-inflammatory treatment with inhaled corticosteroids (ICS) has revolutionized the therapy of asthma and is indicated in almost all patients across all degrees of severity and therapy stages. Nevertheless, there is a broad spectrum of ICS molecules, dosages, combination partners, application concepts (maintenance therapy and/or as-needed therapy), and devices. Thus, there is a large number of variables, whose clinical significance is often unclear. This overview will therefore present clinically relevant aspects in the use of ICS and their combination partners.
Description
Abhinav Singla
Department of Pneumonology, Otto-von-Guericke-University, Magdeburg, Germany
Sabine Stegemann-Koniszewski
Department of Pneumonology, Otto-von-Guericke-University, Magdeburg, Germany
Eva Lücke
Department of Pneumonology, Otto-von-Guericke-University, Magdeburg, Germany
Sascha Kahlfuss
Department of Pneumonology, Otto-von-Guericke-University, Magdeburg, Germany
Jens Schreiber
Department of Pneumonology, Otto-von-Guericke-University, Magdeburg, Germany
Keywords
Bronchial asthma, inhaled corticosteroids, MART-treatment, AIR-treatment